Abstract:OBJECTIVE To evaluate the effect of recombinant bovine basic fibroblast growth factor (rbFGF) on accelerating healing of burn wounds, donor sites and chronic dermal ulcers in multicenters. METHODS One thousand and twenty-four patients with burns, donor sites and chronic dermal ulcers were recruited for this prospective and multicenter clinical trial and another 641 patients with the similar wounds were used as controls. All patients were divided into three groups: burn group, donor site group, and chronic dermal ulcer group. In the burn group, 654 patients with superficial second-degree burns(superficial II degree) or deep second-degree burns(deep II degree) were treated topically with either recombinant bovine basic fibroblast growth factor (rbFGF plus vehicle, rbFGF 150 AU/cm2/day, 330 patients) or placebo (vehicle without rbFGF, 324 patients). In the donor site group, 509 patients were treated with rbFGF and 317 patients with placebo in a similar way as described elsewhere. In the chronic dermal ulcer group, 185 patients were treated with rbFGF and the controls were themselves. Photography, histological evaluation and clinical examination were used to evaluate the results of wound healing. RESULTS All of superficial second-degree burns, deep second-degree burns and the donor sites treated with recombinant bovine basic fibroblast growth factor had an accelerated rate of granulation tissue formation and epidermal regeneration as compared with that in the controls. Superficial second-degree burns and deep second-degree burns treated with recombinant bovine basic fibroblast growth factor healed in 9.89 +/- 2.45 and 17.04 +/- 4.56 days, respectively, whereas the average healing time in those receiving placebo was 12.35 +/- 2.74 and 21.21 +/- 4.88 days. The donor sites treated with rbFGF or placebo healed in 10.68 +/- 4.55 and 14.74 +/- 6.46 days, respectively. All chronic dermal ulcers except 12 patients treated with rbFGF healed within 6 weeks. Histological evaluation of punch-biopsy specimens from the burn wounds, donor sites and chronic dermal ulcers seven days after treatment supported the impression of accelerated wound healing after rbFGF treatment. CONCLUSIONS rbFGF is effective in shortening the wound healing time and improving the wound healing quality. Accelerating wound healing is of clinical benefit in reducing the length of hospitalization, costs and emotional burden of the patient.

The Clinical Observation of the Function of the Rb-Egf Used in the Middling Grafted Donor Site

The clinical observation of the basic fibroblast growth factor on skin graft donor site

[Effect of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor on Wound Healing in Patients with Deep Partial Thickness Burn].

Effect of Recombinant Human Epithelium Growth Factor on Livability of Skin Graft

Effects of basic fibroblast growth factor on the healing of partial‐thickness donor sites

Acceleration of deep Ⅱ° burn healing by using recombinant human granulocyte-macrophage colony stimulating factor gel

Recombinant bovine basic fibroblast growth factor accelerates wound healing in patients with burns, donor sites and chronic dermal ulcers.

The clinical study of recombinant bovine basic fibroblast growth factor on wounds healing

[Clinical Application of Meek Skin Grafting Technique].

[The Effects of Epidermal Growth Factor on the Wound Healing of Deep Partial Thickness Burn in Rats].

The observation of the quality after the wound healing of composite transplantion of accellular allo-dermismatrix with auto-microskin on deep burn wound

The Clinical Study of the Relationship Between the Defect of Different Thickness Dermal Tissues and the Proliferative Scar Formation

Efficacy of hemicellulose dressing for wound healing of donor sites of burn or reconstruction

Biologic effect of exogenous bFGF in acceleration of re-epithelialization after partial thickness scald injury

Cografts of artificial dermis matrix and autogenetic split-thickness of repaired skin in severe hand wounds in patients with deep burns

Randomized, multicenter, double-blind, and placebo-controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial-thickness burns and skin graft donor site.

Effects of Rhgm-Csf on Scalding Wound Healing and Neovascularization in Rats

The clinical observation of the basic fibroblast growth factor applying to the late burn

Randomised Placebo-Controlled Trial of Use of Topical Recombinant Bovine Basic Fibroblast Growth Factor for Second-Degree Burns

[Effect of Exogenous Basic Fibroblast Growth Factor on Proliferation and Migration of Endothelial Cells of Partial Thickness Scald in Rats].

[The Influence of Dermal Template on the Expressions of Signal Transduction Protein Smad 3 and Transforming Growth Factor Beta1 and Its Receptor During Wound Healing Process in Patients with Deep Burns].